Introduction {#S1}
============

The IKZF1 gene encodes the Ikaros protein, which acts as a tumor suppressor and master regulator of hematopoiesis ([@R1]--[@R3]). Impaired Ikaros function is associated with the development of high-risk B-ALL, primary immunodeficiency ([@R4]--[@R9]), as well as 5-8% of T-ALL and 11% of early T-cell precursor (ETP) leukemia ([@R10]). The Ikaros protein is a transcription factor that regulates expression of its target genes via chromatin remodeling ([@R11]--[@R20]).

The role of Ikaros in the epigenetic regulation of gene expression has been extensively studied in normal hematopoiesis and B-ALL, but much less so in T-ALL ([@R21]--[@R26]). Ikaros haplo-knockout mice develop T-ALL with 100% penetrance with T-cell differentiation arrested at the CD4-- CD8-- double negative 3 (DN3) stage of development ([@R27]). During the process of malignant transformation to T-ALL, Ikaros haploinsufficient thymocytes lose their remaining wildtype Ikaros allele; thus, T-ALL cells in these mice have an Ikaros-null genotype ([@R27]). Re-introduction of Ikaros into Ikaros-null T-ALL cells from these mice results in the cessation of cellular proliferation, and induction of T-cell differentiation ([@R28]). These data demonstrate that Ikaros is a critical tumor suppressor in T-ALL. Re-introduction of Ikaros into Ikaros-null T-ALL captures the role of Ikaros in transition from the malignant state (Ikaros-null T-ALL) to the non-malignant state (following Ikaros re-introduction). Thus, this is an optimal system for studying Ikaros tumor suppressor function and its role in the cessation of cell growth and the induction of differentiation.

In this report, we use Ikaros-null T-ALL cells to study the role of Ikaros as an epigenetic regulator of gene expression, cellular proliferation, and T-cell differentiation. To understand Ikaros activity over time, we performed extensive analyses at several time points following the re-introduction of Ikaros in Ikaros-null, T-ALL cells. Results revealed previously-unknown Ikaros roles in regulating chromatin accessibility, as well as enhancer and super-enhancer activation. These data led to a new model of Ikaros function as a regulator of gene expression and the epigenetic landscape in leukemia.

Materials and methods {#S2}
=====================

Cell culture and viral transduction {#S3}
-----------------------------------

The JE131 cell line (referred to here as DN3) is an early T-ALL cell line derived from Ikaros knock-out mice that spontaneously develop T-ALL ([@R28]). DN3 cells were transduced using an MSCV-based bicistronic retroviral vector that expresses Ikaros and GFP. Wild-type cells as well as retrovirally-transduced cells were collected at 1-, 2-, and 3-day timepoints for experiments.

Microarray {#S4}
----------

Total RNA was extracted using QIAGEN RNeasy Mini Kit (Qiagen, 74104, Hilden Germany). cDNA was hybridized to the mouse 430 2.0 array.

ChIP-seq {#S5}
--------

ChIP-seq assays for Ikaros and histone modifications were performed using antibodies and methods in Supplemental data and as previously described ([@R29], [@R30]).

ATAC-seq {#S6}
--------

ATAC-seq was performed as previously described ([@R31]) with minor changes, described in Supplemental Data. Samples were sequenced using the Illumina HiSeq 2500 at the sequencing core facility at Pennsylvania State University College of Medicine.

Results {#S7}
=======

Ikaros regulates diverse cellular pathways by binding to upstream regulatory sequences {#S8}
--------------------------------------------------------------------------------------

The tumor suppressor function of Ikaros was studied using an optimal system: Ikaros re-introduction into Ikaros-null mouse T-ALL cells (DN3 cells) ([@R28]). DN3 cells were transduced with retrovirus that contains HA-tagged wild-type murine Ikaros or empty vector (as a negative control). Gene expression, chromatin accessibility, Ikaros occupancy, and global epigenomic signature was compared prior to, and during the 3 days following, Ikaros re-introduction ([Fig. S1](#SD1){ref-type="supplementary-material"}--[S3](#SD1){ref-type="supplementary-material"}). The level of Ikaros protein in DN3 cells following retroviral transduction was similar to its physiological levels in wild-type thymocytes ([Fig. S4](#SD1){ref-type="supplementary-material"}). This assures that the observed effects of Ikaros are not the result of excessive overexpression. Re-introduction of Ikaros into DN3 cells resulted in cessation of cellular proliferation ([Fig. S5a](#SD1){ref-type="supplementary-material"}) and induction of T-cell differentiation ([Fig. S5b](#SD1){ref-type="supplementary-material"}). These results support previously reported effects following Ikaros re-introduction into Ikaros-null T-ALL ([@R28]).

Analysis of genome-wide occupancy revealed dynamic, Ikaros-mediated changes in the regulation of gene expression. To better characterize the interactions between Ikaros and DNA elements, we divided the genome into four categories: Gene Body (GENCODE annotated gene body regions), Promoter (≤3kb up and down stream of TSS regions for each annotated gene), Enhancer (\>3kb away from TSS with overlapping H3K4me^1^ peak signal regions), and Gene Desert (the remainder of the genome). Ikaros binds genome-wide to all four categories of DNA elements and, despite similar Ikaros expression at days 1, 2, and 3, the number of binding sites in each class is significantly larger at day 1 as compared to day 2 and day 3 ([Fig. 1a](#F1){ref-type="fig"}) Ikaros primarily binds to promoter/enhancer regions at day 1 and day 2, but predominantly binds to gene desert regions at day 3 ([Fig. 1b](#F1){ref-type="fig"}). Interestingly, Ikaros occupancy at the promoters of its target genes is quite diverse during the 3 days following its re-introduction ([Fig. 1c](#F1){ref-type="fig"}). This suggests that Ikaros transiently and sequentially regulates diverse sets of its target genes. Motif analysis of ChIP-seq peak regions shows enrichment for Ikaros consensus binding sequences (--GGAA-- and --GGGA--) (Fig. 1d, [Fig. S6](#SD1){ref-type="supplementary-material"}). Ikaros binding to the promoters of its target genes on day 1 can result in either transcriptional repression or activation ([Fig. 1e](#F1){ref-type="fig"}).

Gene Ontology (GO) term ([Fig. S7](#SD1){ref-type="supplementary-material"}) and Pathway Enrichment analysis ([Fig. S8](#SD1){ref-type="supplementary-material"}) as well as GSEA (Gene Set Enrichment Analysis) ([Fig. S9](#SD1){ref-type="supplementary-material"}--[S10](#SD1){ref-type="supplementary-material"}) showed Ikaros regulating stem cell pluripotency, multiple cancer pathways, and T-cell differentiation. Together, these data demonstrate that Ikaros has the strongest effect immediately after re-introduction into leukemia cells. This suggests that alterations in gene expression and the epigenetic landscape (described below) following Ikaros re-introduction are a result of its tumor suppressor activity. Results show that Ikaros can regulate different sets of genes depending on the stage of differentiation.

Ikaros has pioneering activity {#S9}
------------------------------

A "typical" transcription factor (TF) binds to open chromatin resulting in altered expression of its target genes ([@R32], [@R33]). However, a few TFs are able to bind to condensed chromatin, and induce chromatin de-condensation and increased accessibility ([@R34], [@R35]). This is often associated with the induction of chromatin modifications that lead to the early activation process, or "gene priming", which is characterized by *de novo* formation of the H3K4me^1^ mark ([@R32], [@R36], [@R37]). Such TFs are called Pioneer TFs and usually function as master regulators of tissue differentiation (e.g. Gata and FoxA factors) ([@R32], [@R38]--[@R40]). Because Ikaros functions as a master regulator of hematopoiesis, we tested the hypothesis that Ikaros functions as a Pioneer TF to produce *de novo* open chromatin. Chromatin accessibility was measured using ATAC-seq ([@R31], [@R41]). To determine if a transcription factor has pioneer activity, it is essential to determine the chromatin state before and after the factor is expressed in a cell ([@R32]). Binding of a transcription factor to closed chromatin that results in the formation of open chromatin is the critical test for pioneer activity ([@R34]--[@R36]). Our data show that Ikaros binding at day 1 following its re-introduction in Ikaros-null T-ALL cells induces *de novo* open chromatin (positive ATAC-seq signal) in over 3400 regions with previously closed chromatin (negative ATAC-seq signal) at day 0 (prior to Ikaros re-introduction) ([Fig. 2a](#F2){ref-type="fig"}). Induction of open chromatin via Ikaros binding was associated with *de novo* formation of H3K4me^1^, H3K4me^3^, and, to a lesser extent, H3K27ac marks ([Fig. 2a-b](#F2){ref-type="fig"}). Motif analysis showed enrichment of Ikaros' core binding motif in the *de novo* ATAC-seq peak regions ([Fig. 2c](#F2){ref-type="fig"}). Most of the Ikaros-induced *de novo* open chromatin regions are located within promoters or enhancers ([Fig. 2d](#F2){ref-type="fig"}). Ikaros-induced *de novo* open chromatin at distal regulatory regions regulates genes involved in cellular differentiation and signaling pathways that control cellular proliferation ([Fig. 2e-f](#F2){ref-type="fig"}).

We analyzed whether Ikaros binding that produces *de novo* open chromatin has a lasting effect. Results showed that Ikaros binding at day 1 is transient, and that over 90% of Ikaros-induced *de novo* open chromatin sites are not occupied by Ikaros at day 2 and day 3 ([Fig. S11](#SD1){ref-type="supplementary-material"}). However, despite a lack of Ikaros occupancy, open chromatin induced by Ikaros binding at Day 1 continued to persist at over 600 sites at day 2, and at over 200 sites at day 3 ([Fig. S11](#SD1){ref-type="supplementary-material"}). Overall, the data in [Fig. 2](#F2){ref-type="fig"} demonstrate that Ikaros binds to closed chromatin which results in *de novo* chromatin accessibility at promoters and distal regulatory regions and the priming of these elements by induction of H3K4me^1^. The transient Ikaros binding at day 1 has a long-lasting effect on chromatin accessibility during induction of differentiation and cessation of cellular proliferation. These data, support Ikaros' role as a Pioneer TF. The long-lasting effect of Ikaros pioneering activity suggests that Ikaros sets the stage for the continuation of T cell differentiation.

Ikaros regulates *de novo* formation and depletion of enhancers {#S10}
---------------------------------------------------------------

Ikaros re-introduction into Ikaros-null T-ALL, results in the formation of a large number of *de novo* enhancers as evidenced by *de novo* H3K4me^1^ enriched sites, as compared to wild-type DN3 cells ([Fig. 3a](#F3){ref-type="fig"}). The *de novo*-formed enhancers showed enrichment of Ikaros' core binding motif ([Fig. 3b](#F3){ref-type="fig"}). Analysis revealed over 6000 *de novo* enhancers with Ikaros occupancy and H3K4me^1^ enrichment ([Fig. 3c-d](#F3){ref-type="fig"}). *De novo* enhancer regions are significantly enriched with Ikaros peaks, as compared to random genomic regions ([Fig. S12](#SD1){ref-type="supplementary-material"}). These data strongly suggest that Ikaros DNA binding at day 1 directly induces formation of *de novo* enhancers, and directly determines the enhancer landscape during induction of T-cell differentiation.

Further analyses showed that re-introduction of Ikaros into DN3 cells can produce the opposite effect --- a depletion of a large number of existing enhancers, as evidenced by the loss of H3K4me^1^ enrichment ([Fig. 3e](#F3){ref-type="fig"}). Depleted enhancers showed enrichment of the Ikaros' consensus DNA-binding motif ([Fig. 3f](#F3){ref-type="fig"}). Over 800 depleted enhancers showed a loss of H3K4me^1^ enrichment concomitant with direct Ikaros binding ([Fig. 3g](#F3){ref-type="fig"}, [S13](#SD1){ref-type="supplementary-material"}). A permutation assay confirmed significantly higher enrichment for Ikaros' occupancy at depleted enhancers as compared to random genomic regions ([Fig. S14](#SD1){ref-type="supplementary-material"}). Together, these results indicate a direct role for Ikaros in enhancer depletion.

A dynamic analysis of the epigenetic signature and Ikaros occupancy of *de novo* and depleted enhancers showed that Ikaros binding to these regions is transient. Most of the *de novo* and depleted enhancers showed no Ikaros binding at day 2 ([Figures S15](#SD1){ref-type="supplementary-material"}--[S16](#SD1){ref-type="supplementary-material"}). However, the epigenetic changes induced by Ikaros binding at day 1 were preserved at day 2 in 37% and 42 % of *de novo* and depleted enhancers, respectively. At day 3---two days after the loss of Ikaros binding---over 20% of Ikaros-induced *de novo* enhancers and 12% of Ikaros-depleted enhancers maintained the epigenetic signature that was induced by Ikaros binding to these regions at day 1. These data demonstrate the long-lasting effect of Ikaros binding on the *de novo* formation and depletion of enhancers.

Ikaros binding induces *de novo* formation of active enhancers {#S11}
--------------------------------------------------------------

Enhancers can be in a "poised" state (enriched for H3K4me^1^ but not H3K27ac) or an "active" state (enriched for both H3K4me^1^ and H3K27ac) ([@R33], [@R42]). Poised enhancers do not affect gene expression, while active enhancers positively regulate transcription of target genes. We analyzed the effect of Ikaros on the *de novo* formation of active (*de novo*-activated) enhancers and on the activation of previously poised (poised-activated) enhancers. Re-introduction of Ikaros into DN3 cells results in the formation of over 13000 *de novo*-activated enhancers ([Fig. 4a](#F4){ref-type="fig"}). *De novo*-activated enhancers have a positive effect on expression of genes near their location ([Fig. 4b](#F4){ref-type="fig"}) and have enrichment for the Ikaros core binding motif ([Fig. 4c](#F4){ref-type="fig"}). Over 3000 *de novo*-activated enhancers had *de novo* enrichment of both H3K4me^1^ and H3K27ac concomitant with Ikaros occupancy ([Fig. 4d-e](#F4){ref-type="fig"}). This represents 22% of all *de novo*-activated enhancers and is consistent with significantly higher enrichment for Ikaros occupancy at these regions ([Fig. S17](#SD1){ref-type="supplementary-material"}). This shows that Ikaros binding directly induced the *de novo* formation of a very large number of active enhancers as a part of its tumor suppressor/differentiation function.

Ikaros induces activation of "poised" enhancers {#S12}
-----------------------------------------------

The re-introduction of Ikaros resulted in the activation of 5541 enhancers that were previously in a "poised" state (H3K4me^1^+/H3K27ac--) ([Fig. 5a](#F5){ref-type="fig"}). Activation of poised enhancers positively regulates expression of the genes near these enhancers ([Fig. 5b](#F5){ref-type="fig"}). A motif analysis revealed a strong enrichment for the core Ikaros binding motif ([Fig. 5c](#F5){ref-type="fig"}). Ikaros binding directly resulted in the activation of 942 enhancers that were previously in a "poised" state ([Fig. 5d-e](#F5){ref-type="fig"}, [S18](#SD1){ref-type="supplementary-material"}). This represents 18% of all activated enhancers and indicates that Ikaros plays a critical role in the direct activation of poised enhancers.

We analyzed the dynamic effect of Ikaros binding on *de novo*-activated and poised-activated enhancers. Ikaros binding at day 1, which results in enhancer activation, is transient, because most Ikaros-induced active enhancers at day 1 showed no Ikaros binding at day 2 ([Fig. S19](#SD1){ref-type="supplementary-material"}--[S20](#SD1){ref-type="supplementary-material"}). However, the epigenetic changes induced by Ikaros binding at day 1 were strongly preserved at day 2 in 42% and 74.5 % of *de novo*-activated and poised-activated enhancers, respectively. At day 3, two days after the loss of Ikaros binding, over 10% of Ikaros-induced *de novo*-activated and 39.5% of Ikaros-induced poised-to-activated enhancers maintained the epigenetic signature that was induced by Ikaros binding. These data demonstrate the long-lasting effect of Ikaros binding on enhancer activation, which is particularly pronounced on poised-to-activated enhancers ([Fig. S20](#SD1){ref-type="supplementary-material"}). Because enhancer activation has a strong positive effect on target gene expression, these results reveal a novel mechanism by which Ikaros binding regulates the expression of a very large number of genes as part of its tumor suppressor function in T-ALL.

Ikaros binding induces *de novo* formation of super-enhancers {#S13}
-------------------------------------------------------------

Super-enhancers are potent DNA regulatory regions that contain clusters of enhancers that regulate expression of large numbers of cell-specific genes ([@R43]--[@R45]). Ikaros re-introduction in DN3 cells results in *de novo* formation of a very large number (609) of super-enhancers at day 1, as compared to only 29 super-enhancers present in Ikaros-null DN3 leukemia cells ([Fig. 6a](#F6){ref-type="fig"}). Over 90% of the newly-formed super-enhancers showed enrichment for Ikaros occupancy ([Fig. 6b-c](#F6){ref-type="fig"}). Gene expression analysis demonstrated higher expression levels of the genes in close proximity to super-enhancers as compared to genes near all enhancers (super-enhancers and regular enhancers combined) ([Fig. 6d](#F6){ref-type="fig"}), which suggests that Ikaros-induced formation of super-enhancers has a profound, positive effect on expression of genes that are regulated by super-enhancers. Ikaros-induced super-enhancers regulate genes involved in both T-cell differentiation as well as chromatin organization and regulation ([Fig. 6e-f](#F6){ref-type="fig"}).

Analysis of the dynamic effects of Ikaros on the formation of super-enhancers showed that Ikaros binding that results in the *de novo* formation of super-enhancers is longer-lasting than Ikaros binding that results in the activation of "classic" enhancers. Over 90% of Ikaros-induced super-enhancers show Ikaros occupancy at day 2 and have preserved super-enhancer activity. This is in striking contrast to Ikaros occupancy of "regular" enhancers, which is mostly present at day 1 ([Fig. S21](#SD1){ref-type="supplementary-material"} vs. [Fig. S19](#SD1){ref-type="supplementary-material"}--[S20](#SD1){ref-type="supplementary-material"}). At day 3, Ikaros binding to the super-enhancer regions is lost, although 55% of the regions continue to maintain an epigenetic signature characteristic of super-enhancers ([Fig. S21](#SD1){ref-type="supplementary-material"}). These data demonstrate that Ikaros binding produces a strong, long-lasting effect on the formation and maintenance of super-enhancers and suggest that super-enhancers have a critical role in tumor suppression in T-ALL.

Comparative analysis of the enhancer and super-enhancer landscape showed remarkable preservation between mouse and human T-ALL ([Fig S22](#SD1){ref-type="supplementary-material"}). There is also a high similarity in the enhancer/super-enhancer landscape between DN3 cells, following Ikaros re-introduction, and mouse thymocytes, indicating Ikaros' role in thymocyte differentiation.

Discussion {#S14}
==========

Re-introduction of Ikaros into Ikaros-null mouse T-ALL (DN3) cells provided an opportunity to analyze dynamic changes in Ikaros tumor suppressor activity in T-ALL. This approach identified previously-unknown Ikaros functions in epigenetic regulation of gene expression:

A). Pioneer activity: {#S15}
---------------------

Pioneer TFs initiate the coordination of regulatory mechanisms by opening previously-closed chromatin and by inducing histone modifications that allow the formation of putative enhancers (H3K4me^1^) or promoters (H3K4me^3^) ([@R32]). Ikaros binding at day 1 resulted in the opening of over 3400 previously-inaccessible chromatin sites. This is accompanied by *de novo* enrichment of H3K4me^1^ and H3K4me^3^ modifications, and formation of *de novo* enhancers and promoters. These data strongly support the conclusion that Ikaros has pioneer activity, and triggers coordinated regulation of gene expression resulting in tumor suppression and induction of T-cell differentiation. Ikaros thus joins PU.1, C/EBPa, and EBF1 as a pioneer factor in hematopoiesis ([@R32], [@R46]--[@R52]).

B). Activation of enhancers: {#S16}
----------------------------

Putative enhancers are characterized by the presence of H3K4me^1^ histone modifications. In the absence of H3K27ac, these enhancers are termed "poised" or "primed" enhancers ([@R36], [@R53]). The presence of H3K27ac modifications defines "active" enhancers that positively regulate transcription of their target genes ([@R36], [@R53], [@R54]). Our data showed that Ikaros binding to DNA can either induce *de novo* formation of active enhancers (transforming H3K4me^1^--/H3K27ac-- DNA sites into H3K4me^1^+/H3K27ac+ sites) or activate "poised" enhancers (H3K4me^1^+/H3K27ac--). This is a novel mechanism by which Ikaros regulates gene expression. Ikaros binding to active enhancers has been observed in the past ([@R55], [@R56]), but our results demonstrate for the first time that Ikaros DNA-binding directly induces the formation of active enhancers.

C). Formation of super-enhancers: {#S17}
---------------------------------

Super-enhancers are clusters of enhancers with very high levels of H3K27ac ([@R57]--[@R59]). The role of super-enhancers in T-ALL and the targeting of super-enhancers as a treatment for T-ALL have been proposed ([@R44], [@R45]). Our data demonstrated that Ikaros induces the formation of super-enhancers as a part of its tumor suppressor function and induction of T-cell differentiation. Because super-enhancers regulate target genes more strongly than "regular" enhancers ([Fig. 6d](#F6){ref-type="fig"}) ([@R26]), the role of Ikaros in the formation of super-enhancers is an important, novel aspect of its function.

Our data also demonstrate a role for Ikaros in *de novo* enhancer formation and depletion, but this was less pronounced than the above-outlined Ikaros activities.

In conclusion, our results identify novel Ikaros functions in the epigenetic regulation of gene expression ([Fig. 7](#F7){ref-type="fig"}). These include Ikaros' ability to induce formation of activated enhancers and super-enhancers, and thus act as a positive regulator of gene expression when associated with enhancer and super-enhancer regions. It is likely that Ikaros regulates the enhancer/super-enhancer landscape by recruiting chromatin remodeling complexes. One possible candidate is the SWI/SNF complex, which is reported to associate with Ikaros. Further experiments will be directed toward identification of such complex(es). The dynamic approach used to study Ikaros' effect on epigenetic signature, chromatin accessibility, and gene expression over several time points was crucial in uncovering these previously-unknown Ikaros functions. This suggests that the optimal method for determining the function of tumor suppressors and/or oncogenes is to perform dynamic analyses of their effect in gain-of-function and/or loss-of-function experiments. Future analyses in different hematopoietic malignancies will help to provide a more complete picture of Ikaros' role in tumor suppression.
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![Dynamic regulation of gene expression by Ikaros following re-introduction into Ikaros-null T-ALL cells.\
**(a-b)** Dynamic changes in Ikaros binding to different genome regions. Number of Ikaros binding peaks within Promoters, Enhancers, Gene Body and Gene Desert regions following Ikaros re-introduction. **(c)** Ikaros binds the regulatory elements of different target genes during each of the days following its re-introduction into DN3 cells. The number of Ikaros target genes during each day is shown. **(d)** Motif analysis of Ikaros binding sites at day 1. **(e)** Differentially expressed gene analysis at day 1 vs. day 0.](nihms-1524483-f0001){#F1}

![Ikaros functions as a pioneer transcription factor.\
**(a)** Heat maps of Ikaros ChIP-seq, ATAC-seq, H3K4me^1^and H3K27Ac ChIP-seq signals at open chromatin regions gained at day 1 vs. day 0. **(b)** Examples of *de novo* open chromatin regions and associated genes. Ikaros-induced epigenetic changes are shaded in grey. **(c)** Motif analysis for *de novo* open chromatin regions. **(d)** *De novo* open chromatin regions classified by function of the DNA element. **(e-f)** Gene ontology and pathway enrichment analysis of genes associated with *de novo* open chromatin regions.](nihms-1524483-f0002){#F2}

![Ikaros binding induces *de novo* formation and depletion of enhancers.\
**(a)** Heatmaps of H3K4me^1^ ChIP-seq signals at genome wide *de novo* enhancer regions at day 1, after Ikaros introduction, vs. day 0. Signals are centered on H3K4me^1^ peaks at day 1. **(b)** Motif enrichment analysis for *de novo* enhancer regions. **(c)** Heatmaps of Ikaros and H3K4me^1^ ChIP-seq signals at *de novo*-formed enhancers with Ikaros direct binding regions at day 0 vs. day 1. Signals are centered on Ikaros peaks at day 1. **(d)** Examples of *de novo*-formed enhancers that are induced by Ikaros binding. Ikaros-induced epigenetic changes are shaded in grey. **(e)** Heatmaps of H3K4me^1^ ChIP-seq signals at genome wide depleted enhancer regions at day 1, after Ikaros introduction, vs. day 0. Signals are centered on H3K4me^1^ peaks at day 0. **(f)** Motif enrichment analysis for depleted enhancer regions. **(g)** Heatmaps of Ikaros and H3K4me^1^ ChIP-seq signals at depleted enhancers with Ikaros direct binding regions on day 1 vs. day 0. Signals are centered on Ikaros peaks at day 1.](nihms-1524483-f0003){#F3}

![Ikaros binding induces *de novo* formation of active enhancers\
**(a)** Heatmaps of H3K4me^1^ and H3K27Ac signals at genome wide *de novo* formed activated enhancer regions at day 1, after Ikaros introduction, vs. day 0. Signals are centered on H3K4me^1^ peak at day 1. **(b)** Expression values for genes associated with activated enhancer regions at day 1 (red) vs. day 0 (black). **(c)** Motif analysis for activated enhancer regions. **(d)** Heatmaps of Ikaros, H3K4me^1^ and H3K27Ac ChIP-seq signals at *de novo* formed activated enhancers with Ikaros direct binding regions at day 1 vs. day 0. Signals are centered on Ikaros peaks at day 1. **(e)** Examples of *de novo*-formed active enhancers that are induced by Ikaros binding and associated genes.](nihms-1524483-f0004){#F4}

![Ikaros binding induces activation of "poised" enhancers\
**(a)** Heatmaps of H3K4me^1^ and H3K27Ac ChIP-seq signals at genome wide activated enhancer regions (from previously "poised state") at day 1, after Ikaros introduction, vs. day 0. Signals are centered on H3K4me^1^ peaks at day 1. **(b)** Increased expression of genes associated with activated enhancer regions at day 1 (red) vs. day 0 (black). **(c)** Motif analysis for activated enhancer regions. **(d)** Heatmaps of Ikaros, H3K4me^1^ and H3K27Ac ChIP-seq signals at activated enhancer regions (from the previously "poised" state at day 0) with Ikaros direct binding at day 0 vs. day 1 after induction of Ikaros. Signals are centered on Ikaros peaks at day 1. **(e)** Examples of activated enhancers (from the previously "poised" state at day 0) that are activated by Ikaros binding and associated genes.](nihms-1524483-f0005){#F5}

![Ikaros induces *de novo* formation of super-enhancers.\
**(a)** Super-enhancers at day 0 (black) and day 1 (red). Enhancer regions are plotted in increasing order based on their input-normalized H3K4me^1^ ChIP-Seq signal. Super-enhancers are defined as the population of enhancers above the inflection point of the curve. **(b)** The number of super-enhancers at day 0 (black) and day 1 (red). The number of super-enhancers at day 1, with Ikaros binding (orange) or not (blue). **(c)** Examples of newly-formed, Ikaros-bound, super-enhancers. **(d)** Higher expression of the genes in close proximity to super-enhancers vs. the genes near total enhancers--including both super enhancers and regular enhancers. **(e-f)** Gene ontology and pathway enrichment analysis of genes associated with super-enhancers.](nihms-1524483-f0006){#F6}

![Novel Ikaros functions in the epigenetic regulation of gene expression.\
Results presented here reveal novel functions of Ikaros: *de novo* formation or depletion of enhancers; *de novo* formation of active enhancers; activation of previously "poised" enhancers; and formation of super-enhancers. Ikaros shows pioneering factor activity while binding to promoter and/or enhancer regions.](nihms-1524483-f0007){#F7}
